Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eyebiotech Limited

https://eyebiotech.com/

Latest From Eyebiotech Limited

Merck’s Gardasil Sales In China May Be Impacted By Anti-Corruption Crackdown

HPV vaccine shipments to China are expected to fall after a government crackdown on bribery and corruption caused scientific communication with health care providers to decline. Gardasil also may be hurt by budgetary pressures on distribution of the government-reimbursed vaccine.

Vaccines Compliance

Merck’s Strong Q2 Overshadowed By Gardasil Sales Decline In China

Merck & Co.’s $16.11bn in sales exceeded expectations and prompted a slight increase in 2024 guidance, but HPV vaccine Gardasil came in slightly below consensus due to lower sales in China.

Vaccines Growth

M&A Activity During Q2 Declined In Volume And Valuation

Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.

Evaluate Data M & A

EY: Buyers Need To Fill Revenue Gaps But M&A Targets May Be Scarce

In its Beyond Borders 2024 report, coinciding with the start of the BIO meeting, EY analysts see declining revenues for big pharma, which could be addressed by M&A, if the right takeouts exist.

BIO M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register